

ObsEva SA to Participate in Upcoming Investor Conferences

Geneva, Switzerland and Boston, MA – May 16, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinicalstage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Company Management will be participating in three upcoming investor conferences.

- The RBC Capital Markets Healthcare Conference taking place in New York, May 21-22. ObsEva will present on Wednesday, May 22 at 8 a.m. Eastern Time (ET).
- The Jefferies Healthcare Conference taking place in New York June 4-7. ObsEva will present on June 6 at 8 a.m. Eastern Time (ET).
- The BMO Prescriptions for Success Healthcare Conference taking place in New York June 25. ObsEva will present on Tuesday, June 25 at 4:20 p.m. Eastern Time (ET).

Conference presentations will be webcast, and available in the "Investors" section of ObsEva's website www.ObsEva.com.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSV".

For further information, please contact:

Media Contact Switzerland and Europe: Christophe Lamps Dynamics Group cla@dynamicsgroup.ch +41 22 308 6220 Office +41 79 476 26 87 Mobile



Media Contact U.S.: Marion Janic RooneyPartners LLC mjanic@rooneyco.com +1 212 223 4017 Office +1 646 537 5649 Mobile

CEO Office Contact:

Shauna Dillon Shauna.dillon@obseva.ch +41 22 552 1550

Investor Contact: Mario Corso Senior Director, Investor Relations mario.corso@obseva.com +1 857 972 9347 Office +1 781 366 5726 Mobile